In february 2019 John Wayne Cancer Institute (JWCI) at the Providence Saint John’s Health Center acquired Focal One. Focal One is a medical device for performing a targeted and non-invasive ablation of diseased prostate tissue. Mehran Movassaghi, M.D, MBA, Director of Pacific Men’s Health at Providence Saint John’s, was asked to discuss about it.
Focal One allows the urologist to precisely target the portion of the prostate with the disease. As a consequence, only the prostate areas harboring cancer are treated, living healthy tissue intact.
There are 3 ways to manage prostate cancer: active surveillance, localized and complete treatment. According to Dr. Mehran Movassaghi, “Focal One fills a significant void between active surveillance and radical treatments.”